Boston Scientific Corporation (NYSE:BSX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have received a consensus rating of “Moderate Buy” from the thirty analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, twenty-three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $83.36.

BSX has been the topic of a number of recent research reports. Canaccord Genuity Group decreased their price objective on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. BTIG Research reiterated a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Tuesday, June 16th. Barclays dropped their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Finally, Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a research report on Thursday, May 28th.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 9,800 shares of company stock worth $554,012 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently added to or reduced their stakes in the stock. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Colonial Trust Co SC boosted its stake in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank grew its holdings in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.1%

BSX opened at $44.17 on Monday. Boston Scientific has a 1-year low of $43.89 and a 1-year high of $109.50. The stock has a market capitalization of $65.64 billion, a PE ratio of 18.48, a PEG ratio of 0.85 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average price of $52.87 and a two-hundred day moving average price of $71.13.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts anticipate that Boston Scientific will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.